Response of HT29 colorectal xenograft model to cediranib assessed with 18F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI

NMR in Biomedicine

Volumn 26, Issue 2, 2013, Pages 151-163

  Bokacheva, Louisa ^a   Kotedia, Khushali ^a   Reese, Megan ^a   Ricketts, Sally Ann ^a   Halliday, Jane ^a   Le, Carl H ^a   Koutcher, Jason A ^a,b   Carlin, Sean ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Cediranib; Diffusion weighted MRI; Dynamic contrast enhanced MRI; Histological analysis; HT29 tumors

Indexed keywords

APPARENT DIFFUSION COEFFICIENT; CEDIRANIB; COLORECTAL TUMORS; CONTRAST-ENHANCED; CONTROL GROUPS; DIFFUSION-WEIGHTED MRI; DYNAMIC CONTRAST ENHANCED MRI; ENDOTHELIAL CELL MARKERS; ENDOTHELIAL GROWTH FACTOR; HISTOLOGICAL ANALYSIS; HOECHST; IN-CONTROL; IN-VEHICLE; POST TREATMENT; PRE-TREATMENT; SMALL MOLECULES; SMOOTH MUSCLE ACTINS; SMOOTH MUSCLES; STANDARDIZED UPTAKE VALUES; TIME POINTS; TUMOR NECROSIS; TUMOR PERFUSION; TUMOR RESPONSE;

BLOOD VESSELS; CONTROL SYSTEM SYNTHESIS; DIFFUSION; ENDOTHELIAL CELLS; GADOLINIUM; MUSCLE; POSITRON EMISSION TOMOGRAPHY; PROTEINS; RATS; VEHICLES;

TUMORS;

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CD31 ANTIGEN; CEDIRANIB; GADOLINIUM; HOE 33342; SMOOTH MUSCLE ACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; COLORECTAL CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EXCISION; FOLLOW UP; FRACTIONATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NONHUMAN; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HT29 CELLS; HUMANS; NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RADIOPHARMACEUTICALS; RATS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

RATTUS;

EID: 84872603587     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2830     Document Type: Article

References (52)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285: 1182-1186.
2. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011; 8: 316.
3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008; 8: 592-603.
4. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009; 6: 327-338.
5. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology 2010; 256: 348-364.
6. Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gonen M, Bamboat Z, Shia J, Haviland D, D'Angelica MI, Fong Y, Dematteo RP, Allen PJ, Jarnagin WR. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann. Surg. Oncol. 2011; 18: 2192-2199.
7. Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM. Dynamic contrast-nhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia 2009; 11: 910-920.
8. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009; 27: 3027-3035.
9. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, Dong Q, Meyer CR, Bland PH, McConville P, Geng H, Rehemtulla A, Chenevert TL. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol. Cancer Ther. 2003; 2: 581-587.
10. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Verbeken EK, Bosmans H, Marchal G, Hermans R. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005; 234: 756-764.
11. Bauerle T, Bartling S, Berger M, Schmitt-Graff A, Hilbig H, Kauczor HU, Delorme S, Kiessling F. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur. J. Radiol. 2010; 73: 280-287.
12. Farrar CT, Kamoun WS, Ley CD, Kim YR, Catana C, Kwon SJ, Rosen BR, Jain RK, Sorensen AG. Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. PLoS One 2011; 6: e17228.
13. 18F-fluoromisonidazole. Semin. Nucl. Med. 2007; 37: 451-461.
14. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O'Donoghue J, Ling CC, Humm JL, Zanzonico PB, Koutcher JA. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 2009; 11: 247-259.
15. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005; 5: 152.
16. 18F-fluoromisonidazole PET/CT study. J. Nucl. Med. 2011; 52: 1048-1055.
17. Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol. Cancer Ther. 2005; 4: 1417-1422.
18. Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, Sobrio F, Delamare J, Barre L, Bernaudin M. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl. Med. Biol. 2011; 38: 781-793.
19. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009; 69: 5296-5300.
20. 18F-fluromisonidazole PET imaging as a biomarker for the response to 5, 6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J. Nucl. Med. 2011; 52: 437-444.
21. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005; 65: 4389-4400.
22. Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin. Invest. Drugs 2009; 18: 1549-1557.
23. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2007; 25: 3045-3054.
24. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br. J. Cancer 2007; 97: 65-72.
25. Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jurgensmeier JM, Wedge SR, Barry ST. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol. Cancer Ther. 2007; 6: 2198-2208.
26. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol. Cancer Ther. 2007; 6: 599-606.
27. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr. Opin. Neurol. 2008; 21: 736-744.
28. Bradley DP, Tessier JJ, Lacey T, Scott M, Jurgensmeier JM, Odedra R, Mills J, Kilburn L, Wedge SR. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn. Reson. Imaging 2009; 27: 377-384.
29. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 2009; 27: 2542-2552.
30. Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton JC, Kendrew J, Wedge SR. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed. 2008; 21: 42-52.
31. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010; 12: 466-472.
32. Heilmann M, Kiessling F, Enderlin M, Schad LR. Determination of pharmacokinetic parameters in DCE MRI: consequence of nonlinearity between contrast agent concentration and signal intensity. Invest. Radiol. 2006; 41: 536-543.
33. Noebauer-Huhmann IM, Szomolanyi P, Juras V, Kraff O, Ladd ME, Trattnig S. Gadolinium-based magnetic resonance contrast agents at 7 Tesla: in vitro T1 relaxivities in human blood plasma. Invest. Radiol. 2010; 45: 554-558.
34. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J. Magn. Reson. Imaging 1999; 10: 254-259.
35. Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ. Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia 2007; 9: 382-391.
36. Yankeelov TE, Luci JJ, Lepage M, Li R, Debusk L, Lin PC, Price RR, Gore JC. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn. Reson. Imaging 2005; 23: 519-529.
37. Fan X, Medved M, River JN, Zamora M, Corot C, Robert P, Bourrinet P, Lipton M, Culp RM, Karczmar GS. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn. Reson. Med. 2004; 51: 487-494.
38. Yankeelov TE, Cron GO, Addison CL, Wallace JC, Wilkins RC, Pappas BA, Santyr GE, Gore JC. Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data. Magn. Reson. Med. 2007; 57: 353-361.
39. Beaumont M, Lemasson B, Farion R, Segebarth C, Remy C, Barbier EL. Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI. J. Cereb. Blood Flow Metab. 2009; 29: 1714-1726.
40. Carlin S, Pugachev A, Sun X, Burke S, Claus F, O'Donoghue J, Ling CC, Humm JL. In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nucl. Med. Biol. 2009; 36: 821-831.
41. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res. 2001; 61: 2907-2910.
42. Cheng HL. Improved correlation to quantitative DCE-MRI pharmacokinetic parameters using a modified initial area under the uptake curve (mIAUC) approach. J. Magn. Reson. Imaging 2009; 30: 864-872.
43. Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J, Jin H. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 1996; 27: 838-844.
44. McGrath DM, Bradley DP, Tessier JL, Lacey T, Taylor CJ, Parker GJ. Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. Magn. Reson. Med. 2009; 61: 1173-1184.
45. Fan X, Haney CR, Mustafi D, Yang C, Zamora M, Markiewicz EJ, Karczmar GS. Use of a reference tissue and blood vessel to measure the arterial input function in DCEMRI. Magn. Reson. Med. 2010; 64: 1821-1826.
46. Kershaw LE, Buckley DL. Precision in measurements of perfusion and microvascular permeability with T1-weighted dynamic contrast-enhanced MRI. Magn. Reson. Med. 2006; 56: 986-992.
47. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005; 7: 475-485.
48. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn. Reson. Med. 2000; 43: 828-836.
49. Arlinghaus LR, Li X, Rahman AR, Welch EB, Xu L, Gore JC, Yankeelov TE. On the relationship between the apparent diffusion coefficient and extravascular extracellular volume fraction in human breast cancer. Magn. Reson. Imaging 2011; 29: 630-638.
50. Jaspers K, Aerts HJ, Leiner T, Oostendorp M, van Riel NA, Post MJ, Backes WH. Reliability of pharmacokinetic parameters: small vs. medium-sized contrast agents. Magn. Reson. Med. 2009; 62: 779-787.
51. Berry LR, Barck KH, Go MA, Ross J, Wu X, Williams SP, Gogineni A, Cole MJ, Van Bruggen N, Fuh G, Peale F, Ferrara N, Ross S, Schwall RH, Carano RA. Quantification of viable tumor microvascular characteristics by multispectral analysis. Magn. Reson. Med. 2008; 60: 64-72.
52. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 2006; 66: 3639-3648.